2015 Annual Meeting | 3HC.004 - Multiple Sclerosis Overview I: Basic and Translational Science

Date Monday 04/20/15

Time 08:00 AM - 12:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Half-Day Course

Director(s) Michael K. Racke, MD

Topic(s) General Neurology

Learning Objectives Participants should understand disease mechanisms involved in pathology changes seen in MS, understand possible prevention strategies for MS in family members of patients, understand modifiable environmental factors that may contribute to disease worsening, and understand immune dysfunction in MS and how it relates to approved medications for MS.

CME Available 3.75 CME credits

Recommended Audience Trainee, General Neurologist, Specialist Neurologist

Teaching Styles Didactic

Event Timeline
08:00 AM - 08:10 AM		Introduction Michael K. Racke, MD
08:10 AM - 09:00 AM		Neuropathology of MS Bogdan F. Popescu, MD, PhD
09:00 AM - 09:50 AM		Risk Factors for MS Emmanuelle Waubant, MD, PhD, FAAN
09:50 AM - 10:15 AM		Break
10:15 AM - 11:05 AM		Neuroimunology of MS Michael K. Racke, MD
11:05 AM - 11:55 AM		Immunotherapeutics of MS: Mechanisms of Action Lawrence Steinman, MD, FAAN
11:55 AM - 12:00 PM		Questions and Answers

Faculty Disclosures
Michael K. Racke, MD	Dr. Racke has received personal compensation for serving as an employee of Quest Diagnostics. Dr. Racke has stock in Quest Diagnostics. Dr. Racke has received intellectual property interests from a discovery or technology relating to health care.
Emmanuelle Waubant, MD, PhD, FAAN	The institution of Dr. Waubant has received research support from NIH. The institution of Dr. Waubant has received research support from NMSS. The institution of Dr. Waubant has received research support from PCORI. The institution of Dr. Waubant has received research support from Race to Erase MS. The institution of Dr. Waubant has received research support from Roche. The institution of Dr. Waubant has received research support from Department of Defense. Dr. Waubant has received publishing royalties from a publication relating to health care.
Lawrence Steinman, MD, FAAN	Dr. Steinman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Steinman has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for 180 Life Sciences. Dr. Steinman has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for BioAtla. Dr. Steinman has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Pasithea. Dr. Steinman has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Atreca. Dr. Steinman has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Wilmer Hale Cutler Pickering. Dr. Steinman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bristol Meyers Squibb. Dr. Steinman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Steinman has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for National Academy of Sciences. Dr. Steinman has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Gibson Dunn. The institution of Dr. Steinman has received research support from Roche. The institution of Dr. Steinman has received research support from Novartis. Dr. Steinman has received intellectual property interests from a discovery or technology relating to health care.
Bogdan F. Popescu, MD, PhD	No disclosure on file

��ɫ��

��ɫ��